PD1/VEGFR2 Antibody

Potent Single-Agent Dual Pathway Blockade

Discover UH8



  • PD1 & VEGF pathway synergies have been clinically validated
  • In addition to tumor vasculature conditioning, VEGF is emerging as a master immune checkpoint regulator
  • However, VEGF pathway inhibition comes with dose-limiting tox, limiting opportunities for add-on therapies
  • Combination therapies lead to significant increases in toxicities and treatment delivery times, adding an unsustainable burden to already strained chemotherapy daycare units.
  • UH8 is a single agent, standard IgG, that blocks both pathways synergistically with an enhanced potency/tox profile.


Medical Oncology

While immune checkpoint inhibitors have transformed medical oncology, therapeutic success is still limited to subsets of patients. For this reason, immune-oncology approaches in the clinic are evolving from monotherapies to combinations, attempting to improve potency through dual checkpoint inhibition or diverse pathway targeting.

VEGF, via VEGFR2, establishes an immunosuppressive tumor microenvironment by recruiting suppressor cells, inhibiting T-cell proliferation & cytokine production, and inducing multiple checkpoint inhibitors (PD1, LAG3, TIM3, CTLA4 & TIGIT).

focusing on improved efficacy for

Tumor Targeting

There is a strong rationale for combining PD1/VEGF pathway inhibitors. Aside from a key role in angiogenesis, VEGF is emerging as a master checkpoint regulator in the tumor microenvironment.

Combination therapies represent a rapidly growing

Clinical Trial Space

Combinations of PD1/VEGF pathway inhibitors represented the fastest growing clinical trial space in 2020. A number of these combinations have already been approved for clinical use and many more are following in late-stage clinical trials.

But at what cost?

Combinations often result in efficacy-limiting toxicities & debilitating dosing regimens for patients. The combination of Nivolumab and Ipilimumab in melanoma is associated with high grade 3-4 toxicity and a very high hospital admission rate. Combinations of Atezolizumab and Bevacizumab together with Carboplatin in NSCLC leads to very long treatment times, significantly impacting patient quality of life, but also adding an unsustainable burden on already strained chemotherapy daycare units.
Single agent UH8 has the potential to overcome these unmet needs with increased potency, a minimal adverse event burden and a short infusion time.

our highly-differentiated


UH8 is highly-differentiated from combination therapies with a unique potency v safety profile.

Unique modality

  • 2 paratopes in 1 standard IgG1
  • Exemplary mAb-like properties
  • No complex manufacturing
  • 2 pathways, single agent dosing paves way for add-on therapies


  • High affinity for PD1 drives biodistribution
  • VEGFR2 potency is avidity-driven
  • Low systemic engagement avoids typical VEGF-associated adverse events

Novel mechanism of action

  • Allosteric inhibitor of VEGFR2
  • Unique 2-in-1 drives synergistic engagement of immune cells

the ultrahuman

Management Team

UltraHuman8 have applied their extensive antibody engineering experience to bring together the dual functionalities of immune checkpoint and angiogenesis inhibition in a single agent with increased potency and improved systemic safety.

Jonny Finlay

CEO & Co-Founder

Jonny is a Biotech entrepreneur and founder with two decades of experience in biologics discovery and development in academia, government and pharma. His career has spanned CBER-FDA to Wyeth and Pfizer before founding UltraHuman which in turn gave birth to LockBody Therapeutics and Granular. Jonny has published widely in the field of antibody engineering and acts on the Board of several leading biotech firms.

Jamie Coleman

COO & Co-Founder

Jamie Coleman CoFounded CodeBase, the UK’s largest tech incubator, and UltraHuman which spun out LockBody Therapeutics, now Centessa, and Granular Therapeutics. He was a Board Member of the Edinburgh International Festival, ScotlandIS and the Creative Industries Federation. He has been involved for many years in the interface between software, healthcare and investment.

Orla Cunningham


Prior to joining Ultrahuman 8, Orla was Senior Director of Pfizer’s bio therapeutic optimisation group leading multi-disciplinary teams across diverse research units internally, as well as driving academic collaborations with universities across Ireland & the UK. She has supported discovery programs from conception through to late stage development, with a number of these molecules currently progressing through clinical trial.

the ultrahuman

Scientific Advisory Board

Dr Greg Carven


Dr Gregory J. Carven is currently Chief Scientific Officer (CSO) of Scholar Rock Inc, where he has served in leadership roles since 2014. He has more than 20 years’ experience in the discovery and development of antibody therapeutics and was awarded “Inventor of the Year” in 2016 for his role in the in the development of Keytruda®. Prior to joining Scholar Rock, Gregory led hybridoma based antibody discovery efforts at Pfizer, Merck and Phylogix Inc. Gregory received his PhD in Biological Chemistry from MIT.

Dr Martin Forster


Dr Forster is an Associate Professor at UCL and Consultant Medical Oncologist at UCH NHS Foundation Trust. He specialises in Thoracic and Head and Neck Cancers and has a particular interest in drug development. Dr Forster has been Principal or Chief Investigator of > 70 clinical trials since 2009. He completed his PhD in biomarker development at the Institute of Cancer Research and has many ongoing translational research collaborations. Dr Forster has published widely on cancer biology, translational oncology & clinical studies. He chairs the NIHR Head & Neck Research Group, is UCH Lead for Cancer Research and Joint Lead for the Clinical Trials Theme of the CRUK Lung Cancer CoE.

Dr Stéphane Champiat


Dr Champiat MD, PhD is a physician at the Gustave Roussy Cancer Centre. He completed his medical oncology residency at the University of Nantes in 2014 and taught as an assistant Professor at Paris-Saclay University from 2017-2019. Dr Champiat defended his PhD in Immunology at Paris-Saclay in 2009 and followed this with a postdoc in UCSF.  He joined the Drug Development Department of Gustave Roussy in 2012 with a focus on new immunotherapies and has been principal or co-investigator of > 50 Ph I clinical trials. Dr Champiat’s translational research includes efficacy, mechanisms of resistance and toxicity of immunotherapies.

the ultrahuman


Kevin Johnson


Kevin is a co-founder and Partner at Medicxi, serving on the boards of portfolio companies including Levicept, Capella Bioscience, Apcintex, UltraHuman and Granular Therapeutics.  He also acts as chairman of Crescendo Biologics and sits on the strategic advisory committee of Hilleman Laboratories. Prior to Medicxi, Kevin was CTO at Cambridge Antibody Technology (CAT), where he led the discovery of Humira (marketed by Abbott Pharmaceuticals) and Benlysta (marketed by GlaxoSmithKline).

Francesco De Rubertis

Investor director

Francesco is a co-founder and Partner at Medicxi, serving on the boards of a number of portfolio companies, including Palladio Biosciences, Rivus Pharmaceuticals, Orexia and Inexia, UltraHuman and Granular Therapeutics.  His prior investments include CellZome (acquired by GlaxoSmithKline), GenMab (Copenhagen: GEN.CO), Micromet (acquired by Amgen), Molecular Partners (Swiss:MOLN.SW), and PanGenetics (acquired by Abbott).


Get in Touch

To find out more about UltraHuman8 and our technology, please contact a member of our team using the form or details below and we will be in touch as soon as possible.


UH8 is a single agent that blocks both pathways synergistically, resulting in an improved potency/tox profile; beating PD1 resistance mechanisms & driving unique biology.